Skip to main content
Premium Trial:

Request an Annual Quote

New Releases: Jul 8, 2009

Premium

Exiqon this week announced it was offering BRAF mutation analysis through its CLIA laboratory in California.

UK-based DxS previously announced it was offering its TheraScreen KRAS Test and BRAF test in the US through Exiqon.

"BRAF testing is important because it can identify the subset of colorectal cancer patients who do not have a mutated KRAS gene yet still do not respond to anti-EGFR therapy," Exiqon said in a statement.

According to published studies, BRAF testing can help guide anti-EGFR treatment, with such drugs as cetuximab and panitumumab, for advance colorectal cancer patients.

Non-responsiveness in this subset of patients may have V600E mutation in the BRAF gene. "Testing patients for both KRAS and BRAF provides a more complete analysis of the patient's tumor when evaluating candidates for anti-EGFR therapy," the company said.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.